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Abstract
Hyperthyroidism seems to increase metabolic and cardiovascular risk, while the effects of sub-
clinical hyperthyroidism are controversial. We evaluated metabolic and cardiovascular parameters
in differentiated thyroid carcinoma (DTC) patients with suppressed thyrotropin (TSH) due to levo-
thyroxine (L-T4) therapy. We studied DTC patients and, as a control group, patients with a history
of surgery for non-malignant thyroid pathology. Significantly higher insulin and lower HDL-
cholesterol levels were recorded in DTC subjects. In both groups, insulin levels were significantly
related with body mass index (BMI) but not with age or L-T4 dosage. In DTC patients, a significant
negative correlation was seen between HDL-cholesterol and BMI or L-T4 dosage. In both groups,
intima-media thickness (IMT) correlated positively with age, BMI, glucose levels and systolic blood
pressure. In DTC patients, increased IMT was significantly correlated with glycated hemoglobin
(HbA1c), cholesterol and triglycerides. In DTC patients, C-reactive protein correlated positively
with insulin, insulin resistance, triglycerides and systolic blood pressure, and negatively with HDL-
cholesterol. In both DTC and control subjects, fibrinogen correlated positively with age, BMI,
increased IMT, HbA1c and systolic blood pressure. In DTC subjects, plasma fibrinogen
concentrations correlated positively with insulin resistance, cholesterol and LDL-cholesterol, and
negatively with TSH levels. Our data confirm that the favorable evolution of DTC can be impaired
by a high incidence of abnormal metabolic and cardiovascular data that are, at least in part, related
to L-T4 therapy. These findings underline the need for adequate L-T4 titration.
Introduction
The incidence of thyroid cancer has increased markedly
over the past few decades in several countries, reaching
about 3% of newly diagnosed malignancies [1]. This
increase can be ascribed to the widespread use of sonogra-
phy techniques and of fine needle biopsy of thyroid nod-
ules rather than to known environmental causes of
thyroid cancers. In Italy, the surgical evaluation both of
cold thyroid nodules [2] and of cytologically indetermi-
nate or suspect nodules [3,4] indicates a 5–6% rate of
malignancy. After total thyroidectomy and radioiodine
ablation of thyroid remnants, all thyroid cancer patients
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require lifelong substitutive treatment to prevent
hypothyroidism and thyrotropin (TSH)-related cell
growth stimulation [5]. While thyroid hormone treatment
improves disease-free survival, TSH-suppressive treatment
must take into account the risk of causing iatrogenic dam-
age due to prolonged exogenous hyperthyroxinemia [5].
Obesity and metabolic diseases are serious health prob-
lems in modern society. Indeed, body mass index (BMI),
the most widely used indicator of obesity, has been seen
to be positively related to a greater risk of mortality and
morbidity [6], particularly cardiovascular diseases, diabe-
tes mellitus, stroke and cerebrovascular diseases, osteoar-
ticular diseases and, in some studies, malignancy [7].
Several studies have tried to evaluate the relationship
between metabolic diseases and cancer; however, the data
are conflicting [8-10].
A crucial factor in the outcome of cancer patients is
comorbidity. In some patients, comorbidity may affect
the presentation and recognition of symptoms, have prog-
nostic significance, and increase the complexity of care. In
a study conducted in newly diagnosed patients with dif-
ferentiated thyroid cancer (DTC), one or more concomi-
tant diseases were recorded in 32% [11]. The study
showed that cardiovascular diseases and/or diabetes mel-
litus were present in 6% of DTC patients on diagnosis.
Moreover, the finding that hypertension was the most fre-
quent comorbidity (18%) followed by "other cancers"
(7%), suggests that the concomitance of cardiovascular
disease is probably underestimated [11].
Carotid artery intima-media thickness (IMT) is thought to
predict coronary heart disease and stroke [12] and is an
accepted marker of sub-clinical atherosclerosis [13].
Recently, Franzoni et al. [14] reported that patients with
sub-clinical hypothyroidism showed an increase in
carotid IMT. To our knowledge, no data on carotid IMT in
patients with DTC have been reported.
Our aim was to evaluate several metabolic and cardiovas-
cular parameters, including carotid artery IMT, in a cohort
of patients with DTC. This evaluation was carried out in
addition to the assessment of clinical and biochemical
parameters indispensable for judging the evolution of
DTC. We used a cohort of well-matched subjects with a
history of partial or total surgery for non-malignant thy-
roid pathology as a control group. In both groups of sub-
jects, metabolic parameters and parameters linked to
cardiovascular risk were correlated with thyroid hor-
mones, TSH and levo-thyroxine (L-T4) treatment. Our
data confirm that DTC has a generally favorable evalua-
tion. In addition, the present study shows a high inci-
dence of abnormal metabolic and cardiovascular data,
which are, at least in part, related to L-T4 therapy. Such
comorbidity constitutes an additional risk factor over
time. In particular, low HDL-cholesterol and high insulin
levels, and a significant correlation between fibrinogen
and TSH levels, underline the need for adequate L-T4 titra-
tion.
Methods
Subjects
The study was conducted on a cohort of 106 outpatients
(mean age ± SD: 56.7 ± 13.5 years; range 21–85 years)
with DTC diagnosed < 1 to 25 years earlier. Eighty-four
were females (57.0 ± 13.6 years; range 21–82 years) and
22 were males (57.4 ± 13.7 years; range 28–85 years). His-
tology revealed papillary cancer, follicular variant of pap-
illary cancer, medullary carcinoma, follicular cancer and
insular cancer in 75, 16, 7, 5 and 3 subjects, respectively.
Total thyroid ablation by near-total thyroidectomy and
subsequent radioiodine therapy (for carcinomas of follic-
ular origin) was our standard treatment. Only 16 patients
with carcinomas of follicular origin did not undergo radi-
oiodine therapy, for the following reasons: sub-total thy-
roidectomy (n = 3), no indication (microcarcinomas: n =
12), and refusal (n = 1). All subjects were on a TSH-sup-
pressive L-T4 regimen at the time of examination. In 8
DTC subjects, TSH levels were in the normal (n = 4) or
upper-normal (n = 4) range, owing to lack of compliance
with the L-T4 regimen (n = 5) or recent L-T4 withdrawal
for therapeutic purposes (n = 3). A cohort of 87 outpa-
tients (56.5 ± 15.9 years; range 21–88 years) who had
undergone thyroid surgery for benign thyroid diseases
from < 1 to 51 years earlier, and under L-T4 regimen,
served as a control group. Seventy-eight control subjects
were females (56.1 ± 16.0 years, range 21–88 years) and 9
were males (60.0 ± 14.9 years; range 30–76 years). Sub-
jects with known hypertension, diabetes or lipid abnor-
malities were included in the study. Participants were
classified as non-smokers, former smokers or current
smokers. In all patients, estimated alcohol intake was < 20
g/day. Written informed consent was obtained from all
participants.
Protocol
Clinical examination comprised pharmacological history,
neck palpation, BMI (kg/m2) evaluation and blood pres-
sure measurement after a 15 min rest in the supine posi-
tion by means of a traditional (Riva-Rocci, Erka, Bad Tölz,
Germany) mercury brachial cuff sphygmomanometer.
Neck ultrasonography was performed with a 7.5 MHz lin-
ear probe (AU 5 Idea, Esaote, Genoa, Italy). Carotid artery
IMT was evaluated on both sides by ultrasonography in
the supine position. Color duplex ultrasound scanning
was performed with Caris Plus (Esaote) and a 7.5 MHz
linear-array transducer. The probe was used together with
the resolution box function of the system, and setting
were made in such a way as to produce an optimal pictureThyroid Research 2008, 1:2 http://www.thyroidresearchjournal.com/content/1/1/2
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of the carotid walls. Only the far walls of the artery were
used for calculation. The IMT of the common carotid
artery was defined as the distance between characteristics
echoes from the lumen-intima and media adventitia inter-
faces. IMT was measured over a length of 1 cm just proxi-
mal to the bulb by 3 different measurements over this
length; the mean value was then computed without
including plaques. The IMT over both sides of carotid
arteries was computed and designated as the mean IMT.
Biochemical evaluation, which was performed in the fast-
ing condition in the morning, comprised free-thyroid hor-
mones, TSH, thyroglobulin (Tg), creatinine, glucose,
insulin, glycated hemoglobin (HbA1c), total-cholesterol,
high-density lipoprotein (HDL) cholesterol, triglycerides,
C-reactive protein (CRP), and fibrinogen. Anti-Tg autoan-
tibody (TgAb) was evaluated to identify sera in which a
Tg-recovery test was necessary in order to obtain reliable
Tg values. Calcitonin (CT) was assayed only in DTC of
non-follicular origin. Homeostasis model assessment was
used as a measure of insulin resistance (HOMA-IR), using
the equation: fasting insulin (mU/l) × glucose (mmol/l)/
22.5 [15].
Assays
Serum Tg was assayed by chemiluminescence immu-
noassay (Roche Diagnostics, Mannheim, Germany). The
functional sensitivity of the method is ≤ 0.5 μg/l. In our
laboratory the intra- and inter-assay CVs were 5% and 8%.
On the basis of the functional sensitivity of the methods,
we selected 0.5 μg/l as the cut-off value to discriminate
undetectable from detectable Tg levels. Tg-antibodies
were measured by commercial assay (DiaSorin, Saluggia,
Italy). A concentration of 100 mIU/l IgG to Tg was taken
as the cut-off value. Sera in which TgAb was positive (>
100 mIU/l) were further processed by means of a Tg recov-
ery test in order to determine the right Tg level. Serum CT
assay was performed by chemiluminescence immu-
noassay (DiaSorin); the functional sensitivity of the
method is ≤ 4.0 ng/l. In our laboratory the intra- and
inter-assay CVs were 10% and 15%; in our laboratory the
normal range of CT is < 10.0 ng/l. Free thyroid hormones
and TSH were measured by means of ultra-sensitive
chemiluminescence immunoassays (Roche Diagnostics).
Normal ranges are 0.3–4.2 mIU/l for TSH, and 3.9–6.8
pmol/l and 12.0–22.0 pmol/l for free-T3 (f-T3) and free-
T4 (f-T4), respectively. Serum creatinine (normal range:
44–115 μmol/l), glucose (3.3 – 5.8 mmol/l), cholesterol
(3.4 – 5.2 mmol/l), HDL-cholesterol (> 1.6 mmol/l) and
triglycerides (0.5 – 1.9 mmol/l) were determined by fully
automated Modular P-800 Roche. Low-density lipopro-
tein (LDL)-cholesterol was calculated by means of the
Friedewald equation [16] for those specimens with triglyc-
erides < 2.7 mmol/l. In our laboratory, LDL-cholesterol
values < 3.6 mmol/l are considered normal. HbA1c was
measured by cation-exchange high-performance liquid
chromatography with the TSKgel G7 Variant His column
(Tosoh Co. Tokyo, Japan). Values are reported as percent-
ages; in our laboratory, the normal range of HbA1c is 4.3–
5.8%. Insulin was determined by means of a micro-parti-
cle enzyme immunoassay (Abbot, Abbot Park, IL, USA).
In our laboratory, the normal range of insulin is 2.0–25.0
mU/l. Serum CRP and plasma fibrinogen were analyzed
by commercial assays (Dade Behring, Marburg, Ger-
many). Normal values in healthy subjects are < 3.0 mg/l
for CRP and 180–350 g/l for fibrinogen.
Statistical analysis
Data from DTC and control subjects were analyzed by
means of the Prism 4.0 software (GraphPad Software, San
Diego, CA, USA). To compare absolute and percentage
data, the Mann-Whitney test and χ2 test were used, as
appropriate. Correlation analyses between variables were
carried out by Spearman correlation test. All values
quoted are means ± SEM. Data below the functional sen-
sitivity of the assay were analyzed for statistical purposes
by using the functional sensitivity value. Significance was
taken as P < 0.05. For statistical purposes, the mean IMT
was assigned a score ranging from 1 to 4 according to the
following thickness: 1 = <0.6 mm, 2 = 0.6–0.7 mm, 3 =
0.8–0.9 mm, and 4 = >1.0 mm.
Results
Clinical data
Table 1 reports clinical data recorded in the two groups of
subjects studied. The female-to-male ratio was 4:1 in DTC
patients and 9:1 in controls. The weekly L-T4 dosage was
significantly higher (P < 0.0001) in DTC than in control
subjects. The two groups were well matched in terms of
age, body weight, mean interval from diagnosis to study-
period, incidence of patients with hypertension, diabetes
mellitus or hyperlipidemia, history of cerebrovascular dis-
ease and smoking (Table 1). Both DTC patients (Spear-
man coefficient of correlation rs = 0.23, P = 0.02) and
controls (rs = 0.47, P < 0.0001) showed a significant posi-
tive correlation between BMI and age. In DTC patients,
the weekly L-T4 dosage showed a positive correlation with
BMI (rs = 0.28, P = 0.004) and a negative correlation with
age (rs = -0.22, P = 0.02), while a significant negative cor-
relation was noted in controls only between weekly L-T4
dosage and age (rs = -0.40, P = 0.001). Except for one DTC
patient with slight chronic renal insufficiency (creatinine
186 μmol/l), all subjects showed normal renal function
(data not reported).
Thyroid hormones, TSH, and tumor markers
Table 2 reports the average levels of f-T3, f-T4 and TSH in
DTC and control subjects. As expected, owing to the
higher weekly L-T4 dosage, DTC patients showed more
elevated f-T4 concentrations (P < 0.0001) and more sup-
pressed TSH levels (P < 0.0001) than controls (Table 2).Thyroid Research 2008, 1:2 http://www.thyroidresearchjournal.com/content/1/1/2
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On the basis of undetectable Tg values and negative neck
sonography, 81% of subjects with DTC of follicular origin
were considered disease-free. Active disease was found in
6% of patients with DTC of follicular origin, while in 13%
Tg levels were detectable but less than 1 μg/L (n = 5). Base-
line CT levels were elevated in 57% (n = 4) of DTC
patients with medullary thyroid cancer.
Metabolic parameters
Metabolic parameters are reported in table 3. No signifi-
cant inter-group differences were noted in glucose, HbA1c
or HOMA-IR levels. However, serum insulin levels were
slightly but significantly (P = 0.05) higher in DTC patients
than control subjects (Table 3). Among serum lipid
parameters, the only significant (P = 0.01) difference was
seen in the level of HDL-cholesterol in DTC patients
(Table 3). Insulin levels correlated significantly, both in
DTC (rs = 0.50, P < 0.0001) and control (rs = 0.37, P =
0.001) subjects, with BMI but not with age, L-T4 dosage or
thyroid parameters, with the exception of TSH levels in
controls (rs = 0.30, P = 0.01). Only in DTC patients was
there a significant negative correlation between HDL-cho-
lesterol and both BMI (rs = -0.42; P < 0.0001) and L-T4
dosage (rs = -0.29; P < 0.004), and a significant positive
correlation between HDL-cholesterol and f-T4 levels (rs =
0.22, P = 0.03). The mean IMT score was similar in the
DTC (2.6 ± 0.1) and control (2.5 ± 0.1) groups. In both
groups, the IMT score correlated positively with age (DTC:
rs = 0.68, P < 0.0001; controls: rs = 0.62, P < 0.0001), BMI
(DTC: rs = 0.31, P = 0.002; controls: rs = 0.44, P < 0.0001),
Table 1: Some demographic and clinical data observed in the whole group of DTC subjects and in controls.
DTC subjects Control subjects Significance
Age (years) 57.0 ± 13.7 56.5 ± 15.9 ns
Sex (male-to-female ratio) 4 : 1 9 : 1 ns
Mean diagnosis-study interval (years) 7.0 ± 0.6 9.5 ± 1.0 ns
L-T4 dosage (μg/week) 863 ± 17 658 ± 26 P < 0.0001
BMI (kg/m2) 27.0 ± 0.5 25.6 ± 0.4 ns
Systolic blood pressure (mmHg) 128 ± 2 129 ± 2 ns
Diastolic blood pressure (mmHg) 82 ± 1 80 ± 1 ns
Hypertension 59 (56%) 46 (53%) ns
Use of antihypertensive drugs 53 (50%) 39 (45%) ns
Diabetes mellitus 5 (5%) 7 (8%) ns
Use of antidiabetic drugs 4 (4%) 4 (5%) ns
Use of dyslipidemia drugs 8 (7%) 6 (7%) ns
Smokers 30 (28%) 35 (40%) ns
Current smokers 13 (12%) 17 (19%) -
Former smokers 17 (16%) 18 (21%) -
History of myocardial infarction 0 (0%) 0 (0%) ns
History of stroke 0 (0%) 0 (0%) ns
Age is shown as mean ± SD, while the other continuous data are shown as mean ± SEM; nominal data are shown as absolute numbers and 
percentage values.
Table 2: Serum levels of f-T3, f-T4, and TSH observed in the whole group of DTC subjects and in controls.
DTC subjects Control subjects Significance
f-T3 (pmol/L) 4.4 ± 0.1 4.2 ± 0.1 P = 0.02
Median 4.5 4.1
25th percentile 3.8 3.8
75th percentile 5.1 4.7
f-T4 (pmol/L) 20.1 ± 0.5 17.1. ± 0.5 P < 0.0001
Median 20.5 17.1
25th percentile 18.1 14.5
75th percentile 22.8 18.8
TSH (mIU/L) 1.95 ± 0.86 2.94 ± 0.59 P < 0.0001
Median 0.16 1.30
25th percentile 0.05 0.75
75th percentile 0.60 2.47
Data are reported as mean ± SEM and also as median, 25th percentile and 75th percentile.Thyroid Research 2008, 1:2 http://www.thyroidresearchjournal.com/content/1/1/2
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glucose levels (DTC: rs = 0.22, P = 0.03; controls: rs = 0.31,
P = 0.008), systolic blood pressure (DTC: rs = 0.28, P =
0.005; controls: rs = 0.27, P = 0.02) and the number of
hypotensive drugs administered (DTC: rs  = 0.36, P =
0.0002; controls: rs = 0.31, P = 0.008), while it was unre-
lated to thyroid hormones, TSH, L-T4 dosages, insulin,
HOMA-IR, HDL- and LDL-cholesterol, diastolic blood
pressure or smoking. Only in the DTC patients did IMT
significantly correlate with HbA1c (rs = 0.38; P = 0.0001),
cholesterol (rs = 0.23, P = 0.02) and triglycerides (rs = 0.35,
P = 0.0004).
Inflammatory markers
CRP and fibrinogen levels, evaluated as inflammatory
parameters, are reported in table 3. In both groups of sub-
jects, mean CRP and fibrinogen levels were very similar
and significantly (P < 0.0001) correlated with each other.
Only in DTC patients did CRP positively correlate with
insulin (rs = 0.32, P = 0.001), HOMA-IR (rs = 0.33, P =
0.001), triglycerides (rs = 0.26, P = 0.01) and systolic
blood pressure (rs = 0.20, P = 0.05), and negatively with
HDL-cholesterol (rs = -0.25, P = 0.01). Fibrinogen levels
above the upper normal range (> 350 g/L) were recorded
in a large number of subjects in both the DTC (48% of
cases) and control (47% of cases) groups. In both DTC
and control subjects, fibrinogen correlated positively with
age (DTC: rs = 0.38, P < 0.0001; controls: rs = 0.44, P <
0.0001), BMI (DTC: rs = 0.22, P = 0.02; controls: rs = 0.41,
P = 0.0002), IMT score (DTC: rs = 0.24, P = 0.02; controls:
rs = 0.28 P = 0.02), HbA1c (DTC: rs = 0.39, P < 0.0001;
controls: rs = 0.58, P < 0.0001) and systolic blood pressure
(DTC: rs = 0.29, P = 0.004; controls rs = 0.24, P = 0.03).
Only in DTC subjects did plasma fibrinogen concentra-
tions correlate positively with HOMA-IR (rs = 0.21, P =
0.04), cholesterol (rs = 0.24, P = 0.02) and LDL-choles-
terol (rs = 0.21, P = 0.03), and negatively (P = 0.03) with
serum TSH levels (Figure 1). Only in controls did plasma
fibrinogen levels correlate positively with glucose (rs =
0.29, P = 0.01) levels and the number of hypotensive
drugs administered (rs = 0.40, P = 0.0004).
Discussion
DTC patients have a good prognosis and survival [5].
While DTC can arise in young age, its incidence generally
increases over time [1]. Our DTC subjects ranged from
young to elderly, with a median age of 57 years at the
moment of the present study and a median age of 53 years
on diagnosis. Thyroid carcinomas are 3 times as frequent
in females as in males [1]; a similar ratio was also seen in
our study population. On the basis of undetectable Tg lev-
els and negative neck sonography, in our study a disease-
free condition was observed in 81% of patients with DTC
of follicular origin, which is in line with the reported good
prognosis of this cancer.
The medical therapy of follicular-origin DTC focuses on
TSH suppression by means of L-T4 administration. In a
Table 3: Several metabolic and inflammatory parameters observed in the whole group of DTC subjects and in controls.
DTC subjects Control subjects Significance
Glucose (mmol/L) 4.7 ± 0.1 4.9 ± 0.1 ns
Insulin (mU/L) 8.5 ± 0.5 7.7 ± 0.6 P = 0.05
HOMA-IR [(mU × mmol)/22.5] 1.85 ± 0.13 1.74 ± 0.17 ns
HbA1c (%) 5.7 ± 0.1 5.7 ± 0.1 ns
Cholesterol (mmol/L) 5.36 ± 0.10 5.51 ± 0.11 ns
HDL-cholesterol (mmol/L) 1.71 ± 0.04 2.04 ± 0.09 P = 0.01
LDL-cholesterol (mmol/L) 3.11 ± 0.09 2.93 ± 0.11 ns
Triglycerides (mmol/L) 1.26 ± 0.06 1.21 ± 0.07 ns
CRP (mg/l) 4.4 ± 0.4 4.2 ± 0.3 ns
Fibrinogen (g/L) 355 ± 6 363 ± 10 ns
Data are reported as mean ± SEM.
Correlation between TSH and fibrinogen levels in the cohort  of subjects with DTC Figure 1
Correlation between TSH and fibrinogen levels in 
the cohort of subjects with DTC. While the number of 
pairs and significance for the analysis are reported, two 
experimental values of TSH above 5 mIU/L are not included 
in the graph.
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meta-analysis involving 4174 patients (69% of cases with
TSH < 0.1 mU/L), McGriff et al. [17] found a lower risk of
recurrence, progression and disease-related death among
patients on TSH-suppressive therapy. TSH suppression
therefore remains the gold standard and only in low-risk
tumors with favorable disease evolution is a reduction in
L-T4 dosage countenanced. In our subjects, the L-T4 dos-
age was significantly higher in DTC patients than in con-
trols, and TSH levels were correspondingly lower. Indeed,
suppressed TSH levels (< 0.1 mIU/L) were found in 38%
of DTC patients and only in 3% of controls. In the Colo-
rado study, in which 6% of subjects were on L-T4 treat-
ment, about 40% of these latter presented an abnormal
TSH level [18]. In our study, too, both DTC and control
subjects sometimes showed an abnormal TSH level (e.g.
recent surgery, recent L-T4 withdrawal for radioiodine
therapy, incorrect L-T4 administration, inadequate dos-
age, low compliance); we therefore feel that the efficacy of
L-T4 therapy should be routinely checked to prevent
under- or over-treatment. Exogenous hyperthyroxinemia
accompanied by undetectable TSH levels and/or f-T4
above the therapeutic target has been found in 14% –
21% of patients under L-T4 [19,20]; in this situation, the
objective of treatment should be weighed, on account of
its well-known, potentially dangerous effects [21].
As cardiovascular and metabolic complications may be
induced by L-T4 treatment, our goal was to evaluate DTC
patients with regard to such complications, which could
affect prognosis and life expectancy. Recently, in patients
with thyroid cancer, concomitant diseases were found in
32%, hypertension being the most frequent [11]. In our
study, the same prevalence of hypertension was noted in
DTC and control subjects; hypertension seemed to be
more closely linked to age, BMI and other independent
cardiovascular risk factors, such as IMT and fibrinogen,
than to L-T4 and thyroid hormones. Moreover, our data
do not indicate a marked correlation between DTC and
glucose control, in that the same percentage of subjects
with impaired short- and medium-term glucose control
and HOMA-IR levels was found among DTC and control
subjects matched for BMI and age. Although higher insu-
lin levels were found in DTC patients, the related exoge-
nous hyperthyroxinemia did not induce the insulin
resistance reported by some [22,23] but not all [24,25]
authors with regard to overt endogenous hyperthyroxine-
mia. Moreover, the restoration of euthyroidism does not
generally affect glucose metabolism in patients with DTC
and long-term exogenous hyperthyroxinemia [24] and no
correlation between current L-T4 dosage, TSH or free thy-
roid hormone levels and the evaluated parameters of glu-
cose metabolism is reported [our data]. On the other
hand, we observed a negative correlation between current
L-T4 dosage and glucose levels, as well as a positive corre-
lation between TSH and insulin levels in controls. This
inter-group discrepancy could be due to the small number
of subjects evaluated in our study and in similar studies
[24,26]. By contrast, several literature data are available
on the relationship between glucose metabolism and sub-
clinical [27,28] or overt [26,29] hyperthyroidism, which
are functional thyroid conditions that can be encountered
during L-T4 titration even in subjects who have under-
gone thyroidectomy for malignant or non-malignant dis-
ease. Moreover, it cannot be excluded that fluctuations in
thyroid hormones and TSH might, over time, affect glyco-
metabolic parameters [30].
It is well known that lipid metabolism can be deranged
both in sub-clinical and overt hypothyroidism [31,32].
While L-T4 treatment can improve dyslipidemia, the long-
term effect of the L-T4 load on cardiovascular risk is
unknown [33,34]. Overt hyperthyroidism is associated
with reduced total- and HDL-cholesterol concentrations
[35,36], which normalize after remission of hyperthy-
roidism [37]. Several studies have found no difference in
lipid profiles in sub-clinical hyperthyroidism [38,39],
though reduced cholesterol levels have sometimes been
reported in subjects older than 55 years [40]. In our con-
trol and DTC subjects, cholesterol and triglyceride levels
were not significantly different. However, HDL-choles-
terol levels were significantly lower in DTC patients than
in controls, and correlated negatively with L-T4 dosage
and positively with f-T4. A similar reduction in HDL-cho-
lesterol has been observed in sub-clinical hyperthy-
roidism and in L-T4 treated patients [31]. Recently,
Regalbuto et al. [41] reported an increase in cholesterol
levels in 45% of DTC patients before diagnostic L-T4 dis-
continuation. Other authors, however, have not found
lipid profile changes in DTC patients before [24] and after
[23,24] L-T4 dosage reduction. Moreover, in an old study,
exogenous hyperthyroxinemia was reported to be associ-
ated with low total- and LDL-cholesterol [40]. In overt
hyperthyroidism, triglyceride levels have been reported to
be reduced [42], normal [43] or increased [44].
Non-invasive carotid artery IMT evaluation is an accepted
index of cardiovascular risk and a pre-clinical marker of
arteriosclerosis that is influenced by sex, age, smoking,
lipid profile and hemodynamics [12,13]. As changes in
lipid profile and hemodynamics may occur in thyroid dis-
eases, interest in IMT evaluation has grown. In one cohort
study, increased IMT correlated negatively with f-T4 levels
in euthyroid subjects even after adjustment for age, sex
and lipid profile [45]. However, IMT has been seen to be
greater in both sub-clinical [14,46] and overt hypothy-
roidism [47], and can be reduced by L-T4 treatment
[46,47]. In our study, no difference in IMT score or per-
centage of subjects with carotid stenosis was observed
between the two cohorts of subjects. At present, it cannot
be excluded that longitudinal studies or studies involvingThyroid Research 2008, 1:2 http://www.thyroidresearchjournal.com/content/1/1/2
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larger numbers of subjects might elucidate the direct effect
of thyroid disease and treatment on IMT, over and above
the effect exerted by age, BMI, glucose levels and hyperten-
sion. A linear relationship between thyroid function and
IMT was found in a large cohort of at least 45-year-old
subjects without known thyroid disorders, the highest
IMT values being recorded in hyperthyroxinemia subjects
and the lowest in subjects with elevated TSH levels [48].
In that study, thyroid function was identified as an inde-
pendent risk factor for increased IMT [48]. The association
between IMT and endogenous or exogenous thyroid
hyperfunction is regarded as biologically plausible
because there is a known link between hyperthyroidism
and peripheral vasodilatation, which leads to a decrease
in renal perfusion and activation of the renin-angiotensin
system [49]. Angiotensin II stimulates vascular smooth
muscle cell growth [50] and matrix synthesis [51]. Vascu-
lar hypertrophy is associated with increased vascular stiff-
ness, a phenomenon reported in diffuse toxic goiter [52].
Thus, increased IMT of the carotid artery may merely
reflect an adaptive response to shear and tensile stress
linked to the increase in heart rate and systolic blood pres-
sure generally found in hyperthyroxinemia [52]. Thus, in
DTC, the permanent hyperthyroxinemia needed to main-
tain TSH suppression could increase the risk of both
arrhythmias [21] and arteriosclerosis [53].
CRP levels are thought to be a widely fluctuating marker
of inflammation, and moderate CRP elevation is linked to
subsequent cardiovascular events [28,54]. In subjects with
sub-clinical hypothyroidism, CRP has been found to be
positively related to insulin and higher than in control
subjects with normal thyroid function [28]. However,
CRP levels are not normalized by L-T4 administration in
sub-clinical hypothyroidism [54] and CRP is not related
to TSH levels [27]. On the other hand, in a small group of
15 mostly disease-free DTC patients, Horne et al. [55]
reported higher CRP levels under exogenous hyperthyrox-
inemia than after diagnostic L-T4 withdrawal. According
to these data, it could be hypothesized that a mild inflam-
matory state is present in DTC patients on LT4 therapy.
Our data did not show any difference between subjects on
L-T4 after thyroidectomy for malignant or non-malignant
thyroid disease. However, in DTC subjects, CRP seems to
be modulated by BMI and HOMA-IR, and CRP and fibrin-
ogen are significantly related in both groups of subjects
[our data, [55]].
Fibrinogen is another well-known independent risk factor
for cardiovascular diseases [56]. High fibrinogen levels are
reported in sub-clinical [56] and overt [55,57] hyperthy-
roidism, as well as in sub-clinical [58] and overt [57]
hypothyroidism. About 50% of both our DTC and control
subjects displayed an increase in fibrinogen levels, which
was also positively related to age, BMI, IMT score, HbA1c
and systolic blood pressure. However, only in DTC sub-
jects did plasma fibrinogen levels correlate positively with
HOMA-IR and total- and LDL-cholesterol, and negatively
with TSH levels but not with L-T4 dosages, as also
reported in L-T4 treated hypothyroid patients [59]. Even
in over-treated DTC patients Horne et al. [55] reported an
increase in fibrinogen levels and several other coagulation
factors. On the whole, these data seem to indicate that
TSH-suppression in DTC patients could support an
increased coagulation risk factor, which is probably inde-
pendent of disease status and L-T4 dosage. Finally,
another study has shown that high fibrinogen levels are
linked in hyperthyroidism to an elevation of von Wille-
brand factor and to altered platelet plug formation as an
direct index of endothelial dysfunction [60]. However,
further data need to be considered, including the direct
endothelial effect of TSH [61] and the role of cytokines
such as osteoprotegerin [62,63] and interleukin-6 and
tumor necrosis factor [61].
Conclusion
In conclusion, our study aims to draw greater attention to
metabolic and cardiovascular parameters in both DTC
and control subjects, in whom exogenous hyperthyrox-
inemia could increase metabolic and cardiovascular risk.
In DTC patients, life-long evaluation, as well as L-T4 ther-
apy, is mandatory. Moreover, in medullary thyroid carci-
noma and in low-risk disease-free patients suffering from
DTC of follicular origin, exogenous hyperthyroxinemia
must be avoided even though it does not seem to modify
most hepatic, muscular, cardiac and neuropsychological
parameters [41]. In DTC, slightly increased fT4 levels can,
in the long term, induce an increase in insulin and a
decrease in HDL-cholesterol levels, which are unfavorable
developments. In addition, the significant inverse correla-
tion between fibrinogen and (suppressed) TSH levels,
associated to increases in cytokines [62], fibrinogen [60]
and the endothelial release of von Willebrand factor [55],
seems to document a greater cardiovascular risk in DTC
patients.
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